WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK GSK0.69%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: Related Stocks Indices ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...